Annalice Gandini, Doctoral Researcher Centre de Recherche des Cordeliers shared on LinkedIn:
“Happy to present at ESMO 2026 our retrospective analysis on the multicentric IMMUNODIG cohort evaluating MMR protein-loss patterns as potential biomarkers for immunotherapy intensification in dMMR/MSI metastatic colorectal cancer (mCRC).
Our conclusions:
- Lynch Syndrome (LS) was associated with better IO outcomes, largely explained by baseline characteristics.
- MMR-protein loss pattern (MMR-plp) identify biologically heterogeneous subgroups of dMMR/MSI mCRC beyond LS/sporadic status.
- Exploratory data suggest that in isolated PMS2 or MSH6 loss the benefit from the doublet-IO may be limited.
- MMR-plp, available from routine IHC, deserves further validation as a tool to guide IO intensification.
A huge thanks to all the coauthors and my research team!”
You may also be interested in:
